High-Throughput Screening Reveals Potential Inhibitors Targeting Trimethoprim-Resistant DfrA1 Protein in Klebsiella pneumoniae and Escherichia coli
The DfrA1 protein provides trimethoprim resistance in bacteria, especially Klebsiella pneumoniae and Escherichia coli, by modifying dihydrofolate reductase, which reduces the binding efficacy of the antibiotic. Thus, this study aimed to identify inhibitors of the trimethoprim-resistant DfrA1 protein through high-throughput computational screening of 3,601 newly synthesized chemical compounds sourced from the ChemDiv database. We conducted high-throughput computational optimization and screening of a library containing 3,601 compounds against the DfrA1 protein from K. pneumoniae and E. coli to identify potential drug candidates (DCs). Through this extensive approach, we identified six promising DCs, labeled DC1 to DC6, as potential inhibitors of DfrA1. Each DC demonstrated strong initial binding affinity and favorable chemical interactions with the DfrA1 binding sites when compared to the effective drug Iclaprim (effective antibiotic against DfrA1), used as a control. To validate these findings, we further investigated the molecular mechanisms of inhibition, focusing on the thermodynamic properties of the promising DCs. Furthermore, molecular dynamics simulation (MDS) validated the inhibitory efficacy of these six DCs against the DfrA1 protein. Our results showed that DC4 (an organoflourinated compound) and DC6 (a benzimidazol compound) showed superior efficacy against the DfrA1 protein than the control drug, particularly regarding stability, solvent-accessible surface area, solvent exposure, polarity, and binding site interactions, which influence their residence time and efficacy. Overall, findings of this study suggest that DC4 and DC6 have the potential to act as inhibitors against the DfrA1, offering promising prospects for the treatment and management of infections caused by trimethoprim-resistant K. pneumoniae and E. coli in both humans and animals.